Moderna (NASDAQ: MRNA) filed an 8-K with the SEC on 31 July 2026 to release its second-quarter 2026 results. The headline: the loss came in smaller than Wall Street expected, revenue held roughly flat, and the company trimmed its spending outlook — but its experimental norovirus vaccine stumbled in a late-stage trial.

The numbers

• Revenue: $145 million, versus $142 million a year earlier — essentially flat (about +2% year-on-year). Lower U.S. COVID vaccine sales were offset by deliveries elsewhere.
• EPS (loss per share): $(1.97) on a GAAP basis, versus the roughly $(2.07) loss analysts expected — a narrower loss than forecast, i.e. a beat. A year ago the loss was $(2.13).
• Net loss: $(782) million (about $0.8 billion), an improvement of $43 million (5%) from Q2 2025.
• Costs: R&D fell 7% to $651 million; cost of sales was $93 million, including $41 million of inventory write-downs.
• Cash: $6.9 billion in cash, equivalents and investments at 30 June 2026 (down from $7.5 billion three months earlier).
• Guidance: reiterated a target of up to 10% revenue growth for full-year 2026, improved its 2026 GAAP operating-expense outlook by about $0.2 billion, and raised the expected year-end cash balance to $4.7–5.2 billion.
• Pipeline: the norovirus vaccine candidate (mRNA-1403) did not meet the criteria for early success at a Phase 3 interim look and will enrol more patients; separately, its flu vaccine mFLUSIVA has a U.S. regulatory decision date of 5 August 2026 that could make it Moderna's fifth approved product.

What an 8-K Item 2.02 is

An 8-K is the "breaking news" form U.S. public companies file when something material happens between their big quarterly (10-Q) and annual (10-K) reports. This one is filed under Item 2.02, "Results of Operations and Financial Condition" — the specific item companies use to officially release earnings. The actual figures live in an attached press-release exhibit (Exhibit 99.1). So when you see an 8-K with Item 2.02, it almost always means: the quarterly results just dropped.

Why it matters

Moderna is a company in transition. Its pandemic-era COVID windfall has faded, so today revenue is small relative to its cost base — which is why it is still posting large losses. Two things in this report matter for that story. First, the loss is shrinking and spending is coming down: lower R&D, a better operating-expense outlook, and a higher expected year-end cash balance all point to tighter cost discipline and a longer runway before the cash pile runs low. Second, the pipeline is the real engine: Moderna's future depends on turning experimental mRNA shots into approved, revenue-generating products. The flu vaccine decision on 5 August is a potential win, but the norovirus setback is a reminder that drug development is binary and unforgiving — a single trial miss can erase an entire expected product. None of this tells you where the share price goes; it simply frames the trade-off investors are weighing: cash discipline and a maturing vaccine portfolio against a still-unprofitable business that lives or dies by its clinical readouts.

Beginner takeaway

A "beat" here doesn't mean Moderna made money — it lost about $0.8 billion. It means the loss was smaller than analysts predicted, which markets often reward. For a company like this, the two things worth watching aren't just revenue and profit, but how fast it's burning cash and whether its experimental vaccines succeed in trials.

FAQ

Did Moderna actually make a profit this quarter? No. It reported a net loss of about $782 million. "Beating estimates" only means the loss was smaller than the roughly $2.07-per-share loss analysts had forecast.

Why is revenue so small — only $145 million? Moderna's revenue exploded during the COVID pandemic and has since fallen sharply as demand for COVID boosters normalised. It is now trying to rebuild sales through new vaccines (RSV, flu, combination shots) and international deals.

What does the norovirus vaccine miss mean? Its candidate failed to hit an early bar for success in a Phase 3 trial, so Moderna is adding more patients rather than stopping. It delays and adds uncertainty to a potential future product, but isn't necessarily the end of the program.

What is the 5 August date about? That is a PDUFA date — the deadline by which U.S. regulators aim to decide on Moderna's seasonal flu vaccine, mFLUSIVA. Approval would give the company its fifth marketed product.

As of 31 July 2026. Source: official SEC filing — read it directly here. We summarise filings for education and may make errors, so always verify against the official document. Educational content only — not investment advice, not a buy/sell recommendation.